Evidence map›Paper›PMID 40646168›Full record

ArticleScientific reports2025

Machine learning-based construction of a programmed cell death-related model reveals prognosis and immune infiltration in pancreatic adenocarcinoma patients.

Bing Wang, Zhida Long, Xun Zou, Zhengang Sun, Yuanchu Xiao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bing Wang *Department of Hepatobiliary Pancreatic and Splentic Surgery, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434020, Hubei Province, China.
Zhida Long *Department of Hepatobiliary Pancreatic and Splentic Surgery, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434020, Hubei Province, China.
Xun ZouDepartment of Hepatobiliary Pancreatic and Splentic Surgery, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434020, Hubei Province, China.
Zhengang SunDepartment of Hepatobiliary Pancreatic and Splentic Surgery, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434020, Hubei Province, China.
Yuanchu XiaoDepartment of Hepatobiliary Pancreatic and Splentic Surgery, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434020, Hubei Province, China. 18107167215@163.com.

Funding

Natural Science Foundation of Hubei Province 2022CFB346
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PAAD) is a highly lethal malignancy with limited effective prognostic biomarkers. In this study, 1,034 samples from TCGA-PAAD, GSE62452, GSE28735, GSE183795, and ICGC cohorts were systematically integrated to identify key programmed cell death-related genes (PCDRGs) associated with patient prognosis. Differential expression analysis and Univariate Cox regression analysis identified 17 candidate PCD-related genes significantly associated with overall survival. Using a comprehensive machine learning framework involving 117 algorithmic combinations under a Leave-one-out cross-validation (LOOCV) strategy, we identified the StepCox[both] + Ridge as the best algorithms composition to construct a prognostic model based on six PCDRGs, ITGA3, CDCP1, IL1RAP, CLU, PBK, and PLAU. The model was validated to have robust predictive performance. Risk scores were significantly correlated with clinical features, immune microenvironment characteristics, and chemotherapeutic sensitivity. High-risk patients exhibited worse prognosis and immunosuppressive infiltration patterns. Furthermore, consensus clustering identified two PAAD molecular subtypes with distinct PCDRGs expression patterns and survival outcomes. A nomogram integrating risk score and clinical variables exhibited strong prognostic accuracy for 1-, 3-, and 5-year survival prediction. In summary, we established and validated a PCD-related prognostic signature that effectively stratifies PAAD patients by clinical outcome, immune contexture, and therapeutic response, providing novel insights for personalized management strategies.

Indexed as

AdenocarcinomaApoptosisMachine LearningPancreatic NeoplasmsBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNomogramsPrognosisTumor MicroenvironmentBiomarkers, TumorImmune infiltrationMachine learningPancreatic adenocarcinomaPrognosisProgrammed cell death

Identifiers

PMID40646168
PMCPMC12254473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.